Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GlaxoSmithKline ( (GB:GSK) ) has shared an update.
GlaxoSmithKline (GSK) has announced the purchase of 354,000 of its own ordinary shares as part of its ongoing buyback program. The shares, purchased at prices ranging from 1,597.50p to 1,611.50p, will be held as treasury shares. This move is part of a non-discretionary agreement with BNP Paribas SA, and since September 30, 2025, GSK has acquired a total of 1,946,000 shares. The company now holds 249,410,844 shares in treasury, with 4,065,997,695 shares in issue. This buyback strategy is likely aimed at optimizing capital structure and potentially enhancing shareholder value.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £14.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s strong financial performance and positive earnings call are the most significant factors driving the score. The company’s strategic focus on specialty medicines and shareholder returns, combined with a reasonable valuation and positive technical indicators, support a favorable outlook. Challenges in vaccine sales and regulatory headwinds are noted but are balanced by the company’s innovation and growth initiatives.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
Average Trading Volume: 8,432,680
Technical Sentiment Signal: Buy
Current Market Cap: £65.03B
For an in-depth examination of GSK stock, go to TipRanks’ Overview page.